Innovate UK announced £9.3 million for eight UK medicines manufacturing businesses on 17 November 2026, backing projects that use automation, robotics and digital technologies in laboratory development and production. The UKRI announcement identifies work ranging from synthetic DNA to cell therapies, giving researchers and university partners a map of the manufacturing capabilities receiving public support.
Eight businesses receive medicines manufacturing support
The investment comes through Innovate UK’s Transforming Medicines Manufacturing Innovation programme, within UKRI’s Industrial Strategy 8 Life Sciences programme. The portfolio covers pharmaceutical process development and manufacturing, with an ambition to move from manual laboratory work towards connected, data-driven facilities.
UKRI describes laboratories combining artificial intelligence, robotics, automation and connectivity, with round-the-clock operation as part of the vision. These are development objectives: the businesses are working on systems intended to improve production, formulation and scientific decision-making. The award announcement presents proposed capabilities rather than results from completed manufacturing or clinical evaluations.
What the funded projects aim to develop
The release names eight businesses and describes their technical focus. The projects span both the production of medicines and the systems that support manufacturing staff and process development.
| Business | Proposed development |
|---|---|
| Allos AI | A laboratory using causal AI and automation to develop improved versions of existing medicines while reducing development time and material requirements. |
| Astral Neutronics | Laboratory processes for radiopharmaceutical manufacturing, aimed at strengthening UK production capability. |
| Danu Insights | An automated laboratory using live data and AI to optimise manufacturing processes for cell-based cancer therapies. |
| FourPlus Immersive | An AI-enabled system linking wearable technology and manufacturing data to support operators and production quality. |
| ID Health | An integrated AI and robotics platform for pharmaceutical manufacturing, with personalised medicines as its intended application. |
| Implexis | An automated design and manufacturing platform aimed at developing more patient-friendly cancer medicines. |
| NunaBio | A synthetic DNA manufacturing platform with telemetry, intended to support production at the point of need. |
| Ori Biotech | A demonstration of decentralised cell and gene therapy manufacturing using automated production at connected sites. |
Named partnerships make the collaborative structure more concrete. Astral Neutronics is working with Medicines Discovery Catapult. Danu Insights lists Cell and Gene Therapy Catapult, Lift Therapeutics and Microfluidx. FourPlus Immersive’s partner is listed as Exmoor Pharma Concepts, while Ori Biotech lists Adthera Bio and Cell and Gene Therapy Catapult.
For university teams considering industry engagement, those descriptions distinguish several different entry points: manufacturing-process research, formulation, synthetic DNA production, operator support and production networks. They provide a more useful starting point for collaboration discussions than treating all eight projects as a single laboratory-automation initiative.
How the investment fits the manufacturing programme
Innovate UK Business Connect’s programme overview places Transforming Medicines Manufacturing after the ISCF Medicines Manufacturing Challenge Community, established in 2017 and operating until 2022. The programme combines funding competitions with a Community of Practice offering events, workshops and webinars.
Its stated objectives include reducing the risk of adopting innovative manufacturing technologies and supporting strategically important developments. Focus areas include nucleic acid medicines, digitalisation and automation, intracellular drug delivery, flexible manufacturing technologies and the delivery of complex medicines. That scope places today’s projects within a wider effort to develop and adopt manufacturing methods, connecting research with technology transfer and industrial implementation.
Sector context and stakeholder views
An independent BioIndustry Association report published on 17 November describes existing UK contract manufacturing capabilities. It draws on information supplied between May and September 2026 by 23 organisations across 31 sites. Its coverage includes NHS and university facilities alongside commercial manufacturers and research and technology organisations.
The report distinguishes making a medicine’s active ingredient from formulating, filling or finishing it, and clinical-scale work from commercial supply. It counts organisations rather than output capacity. For researchers selecting a manufacturing partner, those distinctions matter: a count of providers does not establish the volume or stage of production available.
In the report’s foreword, BIA Manufacturing Advisory Committee chair Kit Erlebach describes commercial manufacturers, NHS and university facilities, and Catapults as complementary parts of the development-to-production pathway. His comments concern the sector landscape, rather than the eight awards.
In UKRI’s announcement, Hareklea Markides, Innovate UK’s Innovation Lead for Medicines Manufacturing, attributes the projects’ potential to their combination of life-sciences, advanced-manufacturing and digital expertise. She frames their contribution to UK competitiveness as a prospective benefit of the work.
What research offices and university partners should track
The practical distinction for research offices is between a funded development project and the requirements governing medicine production. MHRA guidance defines good manufacturing practice as the minimum production standard, covering consistent quality, suitability for intended use and conformity with the marketing authorisation or product specification. It describes inspections when organisations apply for manufacturing licences and periodically thereafter according to risk.
For collaborations involving automated manufacturing, the technical development plan therefore needs to be considered alongside the production setting and its quality obligations. CASRAI’s background on data integrity in pharmaceutical manufacturing explains the recordkeeping issues associated with manufacturing systems. A research collaboration agreement provides the contractual context for discussing the partners’ contributions and rights. These are collaboration considerations, rather than additional conditions announced for the eight awards.
A related funding deadline falls on 2 December
For teams seeking a current application opportunity, Business Connect lists a separate Sustainable Medicines Manufacturing Innovation collaborative R&D competition closing on 2 December 2026. Innovate UK and the Department of Health and Social Care plan to invest up to £7 million. UK academic institutions may collaborate, and the consortium must include a UK-registered SME claiming grant funding.
That competition requires grant requests between £500,000 and £1 million and projects lasting nine to 12 months, starting by 1 April 2027 and ending by 31 March 2028. Proposals must evidence sustainability claims with baseline measurements and defined metrics, and identify regulatory challenges and proposed solutions. Those requirements give research offices specific eligibility, measurement and timetable checks for prospective applications to that separate call.
Sources
- UKRI: Funding tomorrow’s medicines manufacturing labs today. 2026-11-17; checked 2026-11-17.
- Innovate UK Business Connect: Transforming Medicines Manufacturing. Undated; checked 2026-11-17.
- BioIndustry Association: UK CDMO landscape 2026: A snapshot of the UK’s contract medicines manufacturing capability. 2026-11-17; checked 2026-11-17.
- MHRA: Medicines: good manufacturing practice and good distribution practice. 2014-12-18; updated 2024-05-13; checked 2026-11-17.
- Innovate UK Business Connect: Sustainable Medicines Manufacturing Innovation: CR&D Round 2. Call opens 2026-10-05; closes 2026-12-02; checked 2026-11-17.







